Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838540 | 1.00 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL1824156 | 0.88 | RIPK1 (0.48) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL9764565 | 0.85 | RIPK1 (0.46) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL29026695 | 0.83 | TYR (0.48) | RIPK1 | |
| SCHEMBL11340864 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28045674 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28039437 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28336920 | 0.81 | HDAC4 (0.41) | RIPK1 | |
| SCHEMBL4578844 | 0.81 | RIPK1 (0.53) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL7235718 | 0.80 | HRH1 (0.50) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| CN-114007660-B | Refreshing composition and method for atomizing refreshing composition by using heat-activated microfluidic cartridge | 宝洁公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-3042894-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| WO-2013157651-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-24 | — | — | WO | disclosed |
| US-8242439-B2 | Method for the determination of the position of unsaturation in a compound | THE UNIVERSITY OF WOLLONGONG (AU) | 2012-08-14 | — | — | US | disclosed |
| US-8242439-B2 | Method for the determination of the position of unsaturation in a compound | THE UNIVERSITY OF WOLLONGONG (AU) | 2012-08-14 | — | — | US | disclosed |
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1035125-A2 | 2-Pyridylsilane, processes for producing and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0987253-A1 | PYRAZOLONE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-6020366-A | Butyric acid matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5968967-A | INHIBIT PLATELET AGGREGATION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0923569-A1 | BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998006711-A1 | BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5162318-A | Which have pulmonary surfactant secretion promoting activity | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0454330-A1 | Benzimidazolinone derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-10-30 | — | — | EP | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | RIPK1 1970/4885TAAR1 3797/4885TRPA1 4710/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | RIPK1 1970/4885TAAR1 3797/4885TRPA1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.